NCT02219503View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

September 30, 2015

Conditions
Chronic Hepatitis C InfectionCompensated Cirrhosis
Interventions
DRUG

Ombitasvir/Paritaprevir/Ritonavir

Tablet; paritaprevir co-formulated with ritonavir and ombitasvir

DRUG

Dasabuvir

Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY